Trial Outcomes & Findings for Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant (NCT NCT03862807)

NCT ID: NCT03862807

Last Updated: 2024-04-22

Results Overview

Serum TTR was assessed using enzyme linked immunosorbent assay (ELISA). The average of the percentage reduction in serum TTR observed at Month 6 and at Month 12 is first calculated for each patient and then the median (95% CI) of these averaged values is summarized for the Safety Analysis Set.

Recruitment status

COMPLETED

Study phase

PHASE3

Target enrollment

24 participants

Primary outcome timeframe

Baseline, Months 6 and 12

Results posted on

2024-04-22

Participant Flow

Participants with hereditary transthyretin-mediated amyloidosis (hATTR amyloidosis) with disease progression post-orthotopic liver transplant were enrolled at nine sites in France, Germany, Italy, Portugal, Spain, Sweden and the United Kingdom.

Participant milestones

Participant milestones
Measure
Patisiran
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Overall Study
STARTED
24
Overall Study
Treated
23
Overall Study
Completed Treatment
22
Overall Study
COMPLETED
23
Overall Study
NOT COMPLETED
1

Reasons for withdrawal

Reasons for withdrawal
Measure
Patisiran
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Overall Study
Not Treated Due to Eligibility Criteria Failure
1

Baseline Characteristics

Patisiran in Patients With Hereditary Transthyretin-mediated Amyloidosis (hATTR Amyloidosis) Disease Progression Post-Liver Transplant

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Patisiran
n=23 Participants
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Age, Continuous
58.1 years
STANDARD_DEVIATION 9.9 • n=39 Participants
Sex: Female, Male
Female
10 Participants
n=39 Participants
Sex: Female, Male
Male
13 Participants
n=39 Participants
Race/Ethnicity, Customized
White
22 Participants
n=39 Participants
Race/Ethnicity, Customized
Asian
1 Participants
n=39 Participants
Race/Ethnicity, Customized
Not Hispanic or Latino
23 Participants
n=39 Participants
Serum Transthyretin (TTR)
192.140 mg/L
n=39 Participants

PRIMARY outcome

Timeframe: Baseline, Months 6 and 12

Population: Safety Analysis Set: All participants who received any amount of patisiran.

Serum TTR was assessed using enzyme linked immunosorbent assay (ELISA). The average of the percentage reduction in serum TTR observed at Month 6 and at Month 12 is first calculated for each patient and then the median (95% CI) of these averaged values is summarized for the Safety Analysis Set.

Outcome measures

Outcome measures
Measure
Patisiran
n=22 Participants
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Average of Month 6 and Month 12 Percentage Reduction From Baseline in Serum Transthyretin (TTR)
91.0 percent reduction
Interval 86.1 to 92.3

SECONDARY outcome

Timeframe: Baseline, Month 12

Population: Participants from the Per Protocol (PP) Analysis Set, all participants in the Safety Analysis Set who missed ≤2 doses of patisiran due to the COVID-19 pandemic during the study, with NIS data available at Month 12.

The NIS is a composite neurologic impairment score that assesses motor weakness (NIS-W), sensation (NIS-S) and reflexes (NIS-R) by physical exam. The minimum and maximum values are 0 and 244, respectively. A higher score indicates a worse outcome.

Outcome measures

Outcome measures
Measure
Patisiran
n=20 Participants
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Change From Baseline in the Neuropathy Impairment Score (NIS) at Month 12
-3.7 score on a scale
Standard Error 2.7

SECONDARY outcome

Timeframe: Baseline, Month 12

Population: Per Protocol (PP) Analysis Set: All participants in the Safety Analysis Set who missed ≤2 doses of patisiran due to the COVID-19 pandemic during the study.

The Norfolk QoL-DN questionnaire is a standardized 35-item patient-reported outcomes measure that is sensitive to the different features of diabetic neuropathy - small fiber, large fiber, and autonomic nerve function. The minimum and maximum values are -4 and 136, respectively. A higher score indicates a worse outcome.

Outcome measures

Outcome measures
Measure
Patisiran
n=21 Participants
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Change From Baseline in Norfolk Quality of Life-Diabetic Neuropathy (Norfolk QoL-DN) Score at Month 12
-6.5 score on a scale
Standard Error 4.9

SECONDARY outcome

Timeframe: Baseline, Month 12

Population: Per Protocol (PP) Analysis Set: All participants in the Safety Analysis Set who missed ≤2 doses of patisiran due to the COVID-19 pandemic during the study.

The R-ODS is comprised of a 24-item linearly weighted scale that specifically captures activity and social participation limitations. The minimum and maximum values are 0 and 48, respectively. A higher score indicates a better outcome.

Outcome measures

Outcome measures
Measure
Patisiran
n=21 Participants
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Change From Baseline in the Rasch-Built Overall Disability Scale (R-ODS) at Month 12
-0.1 score on a scale
Standard Error 1.1

SECONDARY outcome

Timeframe: Baseline, Month 12

Population: Participants from the Per Protocol (PP) Analysis Set, all participants in the Safety Analysis Set who missed ≤2 doses of patisiran due to the COVID-19 pandemic during the study, with COMPASS-31 data available at Month 12.

The COMPASS-31 questionnaire is a measure of autonomic neuropathy symptoms. The questions evaluate 6 autonomic domains (orthostatic intolerance, vasomotor, secretomotor, gastrointestinal, bladder, and pupillomotor). The minimum and maximum values are 0 and 100, respectively. A higher score indicates a worse outcome.

Outcome measures

Outcome measures
Measure
Patisiran
n=20 Participants
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Change From Baseline in the Composite Autonomic Symptom Score (COMPASS-31) at Month 12
-5.0 score on a scale
Standard Error 2.6

SECONDARY outcome

Timeframe: Baseline, Month 12

Population: Per Protocol (PP) Analysis Set: All participants in the Safety Analysis Set who missed ≤2 doses of patisiran due to the COVID-19 pandemic during the study.

Nutritional status of participants was evaluated using the mBMI, calculated as BMI (kg/m\^2) multiplied by albumin (g/L). An increase from baseline in mBMI suggests improvement, and a decrease from baseline suggests worsening.

Outcome measures

Outcome measures
Measure
Patisiran
n=21 Participants
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Change From Baseline in the Modified Body Mass Index (mBMI) at Month 12
4.4 (kg/m^2)*(g/L)
Standard Error 21.8

SECONDARY outcome

Timeframe: From baseline to end of study at Month 13

Population: Safety Analysis Set: All participants who received any amount of patisiran.

An AE is any untoward medical occurrence in a participant or clinical investigational patient administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment.

Outcome measures

Outcome measures
Measure
Patisiran
n=23 Participants
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Percentage of Participants With Adverse Events
100 percentage of participants

Adverse Events

Patisiran

Serious events: 5 serious events
Other events: 23 other events
Deaths: 0 deaths

Serious adverse events

Serious adverse events
Measure
Patisiran
n=23 participants at risk
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Cardiac disorders
Atrial thrombosis
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Cardiac disorders
Cardiac failure
13.0%
3/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Hepatobiliary disorders
Cholangitis
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Immune system disorders
Infusion related reaction
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Infections and infestations
Pneumonia
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Infections and infestations
Urinary tract infection
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Injury, poisoning and procedural complications
Hip fracture
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Nervous system disorders
Syncope
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Renal and urinary disorders
Haematuria
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Renal and urinary disorders
Urinary retention
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Respiratory, thoracic and mediastinal disorders
Atelectasis
4.3%
1/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.

Other adverse events

Other adverse events
Measure
Patisiran
n=23 participants at risk
Participants received patisiran 0.3 milligrams/kilogram (mg/kg) via intravenous (IV) infusion once every 3 weeks (q3w) for 12 months. Dosing was based on actual body weight. For participants weighing 100 kg or more, patisiran was administered at a total dose of 30 mg IV q3w.
Ear and labyrinth disorders
Vertigo
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Gastrointestinal disorders
Abdominal pain
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Gastrointestinal disorders
Bile acid malabsorption
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Gastrointestinal disorders
Diarrhoea
34.8%
8/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
General disorders
Asthenia
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
General disorders
Chest pain
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
General disorders
Fatigue
13.0%
3/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
General disorders
Oedema peripheral
21.7%
5/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
General disorders
Pyrexia
13.0%
3/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Immune system disorders
Infusion related reaction
26.1%
6/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Infections and infestations
Bronchitis
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Infections and infestations
Cystitis
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Infections and infestations
Urinary tract infection
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Injury, poisoning and procedural complications
Fall
13.0%
3/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Injury, poisoning and procedural complications
Skin laceration
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Musculoskeletal and connective tissue disorders
Back pain
21.7%
5/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Nervous system disorders
Headache
13.0%
3/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Renal and urinary disorders
Oliguria
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.
Vascular disorders
Poor venous access
8.7%
2/23 • From baseline to end of study at Month 13.
Safety Analysis Set: All participants who received any amount of patisiran.

Additional Information

Chief Medical Officer

Alnylam Pharmaceuticals Inc.

Phone: 866-330-0326

Results disclosure agreements

  • Principal investigator is a sponsor employee It is intended that after completion of the study, the data are to be submitted for publication in a scientific journal and/or for reporting at a scientific meeting. A separate publication by Institution or PI may not be submitted for publication until after this primary manuscript is published or following 12 months after completion of the study. A copy of any proposed publication based on this study, must be provided and confirmed received at the Sponsor at least 30 days before its submission.
  • Publication restrictions are in place

Restriction type: OTHER